New York, USA - December 17, 2025 - Bacteroides is one of the most important resident bacterial genera in the human gut, playing a key role in maintaining immune homeostasis, regulating energy metabolism, and enhancing the mucosal barrier. Recently, Bacteroides dorei has attracted much attention due to its potential applications in metabolic diseases, inflammatory diseases, and the regulation of intestinal health. Meanwhile, Bacteroides acidifaciens has demonstrated unique advantages in immune regulation and anti-inflammatory research.
However, moving these promising strains from basic research to regulated and scalable drug products remains challenging due to demanding culture requirements, the difficulty of genetic manipulation, and the need for standardized functional assessment.
To overcome the major problems experienced by the industry, Creative Biolabs has upgraded its service system to cover the entire chain from "strain sourcing-characterization-functional assessment-engineering-formulation development-pilot-scale production," including:
• Strain isolation, identification, and quality control: Utilizing 16S rRNA, whole-genome sequencing (WGS), and MALDI-TOF technologies to ensure accurate strain identity and stable genetic background.
• High-standard anaerobic culture system: Applicable to multiple hard-to-culture Bacteroides spp., covering multi-stage project requirements from laboratory scale to scale-up.
• Functional mechanism studies: Including short-chain fatty acid (SCFA) profiling, immune regulation pathways, gene expression, and metabolic activity analysis.
• Development of live biotherapeutic preparations: Covering key steps such as freeze-drying formulation, stability studies, and delivery carrier optimization, providing a basis for future drug delivery routes.
• Construction of engineered strains: Offering strategies such as gene knockout, gene insertion, and site-directed modification strategies to support functional enhancement or mechanism research.
An expert from Creative Biolabs stated, "The pace of research and development for active biological therapies is rapidly increasing, but the industry still faces significant barriers in strain standardization, engineering controllability, and large-scale production. We hope that through this service system upgrade, more promising intestinal strains can truly progress into the drug development pipeline. For instance, both Bacteroides ovatus and Bacteroides dorei have demonstrated highly promising characteristics in fiber metabolism, mucosal barrier repair, and immune regulation, which are worthy of in-depth exploration."
The expert further pointed out, "Our goal is not simply to provide strains, but to offer a replicable, manageable, and scalable R&D path, enabling both scientific research and industrial clients to reduce early exploration costs and invest more resources in mechanism innovation and application breakthroughs."
This service upgrade is not only aimed at scientific research needs but also fully takes into account the regulatory and quality requirements of enterprises in LBP research and development. Creative Biolabs has introduced traceable quality control strategies, batch records, and process designs that meet the needs of future preclinical research in the system construction, laying the foundation for the future transformation from research grade to GMP.
About
Creative Biolabs aims to provide global research institutions and biotech enterprises with more comprehensive and higher-standard R&D support, accelerating innovation and the translation and implementation in the field of microbial therapy.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://live-biotherapeutic.creative-biolabs.com
